SA PRO
Free Account
Hims & Hers Health, Inc.HIMSNYSE
LOADING
|||
Switch Symbol:
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
17 analysts·Moderate coverage
29%
Rating Distribution
Strong Buy
00%
Buy
529%
Hold
1059%
Sell
212%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 69% higher.

Bear Case
$29.00
+14%
Consensus
$43.25
+69%
Bull Case
$60.00
+135%
Price Range17 analysts
Low
Consensus
High
$29.00
$60.00
Current Target
Current Price
$25.54
Upside to Target
$17.71

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Feb 2, 2026BTIG
Hims & Hers price target lowered to $60 from $85 at BTIG
Target:$60.00
+121.5%from $27.09
Jan 8, 2026Wolfe Research
Hims and Hers (HIMS) PT Lowered to $29 at BofA Securities, 'Sales and EBITDA margin expectations are too high'
Target:$29.00
-18.2%from $35.46
Dec 8, 2025Barclays
Hims & Hers initiated with an Overweight at Barclays
Target:$48.00
+22.7%from $39.12
Dec 4, 2025Leerink Partners
Hims and Hers (HIMS) PT Lowered to $41 at Leerink Partners
Target:$41.00
+1.9%from $40.23
Nov 12, 2025Morgan Stanley
Morgan Stanley on Hims and Hers (HIMS): 'October Data Continues to Trend in the Wrong Direction'
Target:$40.00
+0.6%from $39.75
Nov 4, 2025Seaport Global
Hims & Hers price target lowered to $59 from $66 at Seaport Research
Target:$59.00
+32.0%from $44.71
Nov 4, 2025Truist Financial
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
Target:$37.00
-17.3%from $44.73
Nov 4, 2025UBS
Hims & Hers price target raised to $32 from $28 at BofA
Target:$32.00
-27.9%from $44.39
Nov 4, 2025Leerink Partners
Hims and Hers (HIMS) PT Raised to $46 at Leerink Partners
Target:$46.00
+3.6%from $44.39
Jun 24, 2025Truist Financial
Hims & Hers litigation risk 'back on the table', says Truist
Target:$45.00
+4.8%from $42.95
Jun 23, 2025UBS
Hims & Hers legal risk up 'substantially' with cancellation, says Citi
Target:$30.00
-28.5%from $41.98
Jun 4, 2025Needham
Hims & Hers ZAVA Acquisition Deal Expands Its Market Opportunity By $52 Billion: Analyst
Target:$65.00
+21.2%from $53.61
Feb 19, 2025Canaccord Genuity
Hims & Hers Health Stock Hits All-Time Highs: What's Going On?
Target:$68.00
-1.1%from $68.74
Dec 2, 2024Canaccord Genuity
Hims and Hers (HIMS) PT Raised to $38 at Canaccord Genuity
Target:$38.00
+23.3%from $30.81
Nov 5, 2024Piper Sandler
Hims and Hers (HIMS) PT Raised to $21 at Piper Sandler
Target:$21.00
+1.7%from $20.64
Nov 5, 2024Needham
Hims and Hers (HIMS) PT Raised to $28 at Needham
Target:$28.00
+33.6%from $20.96
Oct 29, 2024Leerink Partners
Hims and Hers (HIMS) PT Raised to $26 at Leerink Partners
Target:$26.00
+12.7%from $23.08
Oct 21, 2024Bank of America Securities
Hims and Hers (HIMS) PT Raised to $25 at BofA Securities
Target:$25.00
+12.9%from $22.15
Oct 14, 2024Bank of America Securities
Hims and Hers (HIMS) PT Raised to $23 at BofA Securities
Target:$23.00
+16.0%from $19.82
Oct 14, 2024Truist Financial
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
Target:$23.00
+16.0%from $19.82
Sep 13, 2024Bank of America Securities
Hims & Hers price target lowered to $20 from $24 at BofA
Target:$20.00
+26.4%from $15.82
Aug 27, 2024Citigroup
Citi on Hims and Hers (HIMS) Post Lilly (LLY) News: 'Single-dose Zepbound Vials a Shot Across the Bow for the Compounders'
Target:$20.00
+34.0%from $14.93
Aug 7, 2024Jefferies
Hims and Hers (HIMS) PT Lowered to $18 at Jefferies
Target:$18.00
+12.2%from $16.04
Aug 6, 2024Deutsche Bank
Hims and Hers (HIMS) PT Raised to $23 at Deutsche Bank
Target:$23.00
+36.3%from $16.88
May 22, 2024Canaccord Genuity
Hims and Hers (HIMS) PT Raised to $24 at Canaccord Genuity
Target:$24.00
+36.7%from $17.56

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance